

Alexander L Gerbes

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7391669/publications.pdf>

Version: 2024-02-01

107
papers

11,467
citations

46918

47
h-index

29081

104
g-index

113
all docs

113
docs citations

113
times ranked

7797
citing authors

#	ARTICLE	IF	CITATIONS
1	A Simple Prognostic Scoring System for Hepatocellular Carcinoma Treated with Selective Internal Radiation Therapy. <i>Digestive Diseases</i> , 2022, 40, 322-334.	0.8	3
2	p70 Ribosomal Protein S6 Kinase Is a Checkpoint of Human Hepatic Stellate Cell Activation and Liver Fibrosis in Mice. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2022, 13, 95-112.	2.3	5
3	Marked Increase of Gamma-Glutamyltransferase as an Indicator of Drug-Induced Liver Injury in Patients without Conventional Diagnostic Criteria of Acute Liver Injury. <i>Visceral Medicine</i> , 2022, 38, 223-228.	0.5	3
4	Acute liver injury following methylprednisolone pulse therapy: 13 cases from a prospectively collected cohort. <i>European Journal of Gastroenterology and Hepatology</i> , 2022, 34, 457-461.	0.8	3
5	Challenges and Future of Drug-Induced Liver Injury Research—Laboratory Tests. <i>International Journal of Molecular Sciences</i> , 2022, 23, 6049.	1.8	10
6	Monocyte-Derived Hepatocyte-Like Cell Test: A Novel Tool for in vitro Identification of Drug-Induced Liver Injury in Patients with Herbal or Dietary Supplements. <i>Digestion</i> , 2021, 102, 650-653.	1.2	4
7	Clinical features and evolution of bacterial infection-related acute-on-chronic liver failure. <i>Journal of Hepatology</i> , 2021, 74, 330-339.	1.8	76
8	Further evidence for the hepatotoxic potential of metamizole. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 1587-1588.	1.1	4
9	PREDICT identifies precipitating events associated with the clinical course of acutely decompensated cirrhosis. <i>Journal of Hepatology</i> , 2021, 74, 1097-1108.	1.8	149
10	Antimitochondrial Rather than Antinuclear Antibodies Correlate with Severe Drug-Induced Liver Injury. <i>Digestive Diseases</i> , 2021, 39, 275-282.	0.8	12
11	Liver Injury Associated with Metamizole Exposure: Features of an Underestimated Adverse Event. <i>Drug Safety</i> , 2021, 44, 669-680.	1.4	16
12	SEPT6 drives hepatocellular carcinoma cell proliferation, migration and invasion via the Hippo/YAP signaling pathway. <i>International Journal of Oncology</i> , 2021, 58, .	1.4	13
13	Ashwagandha-Induced Liver Injury: Self-Reports on Commercial Websites as Useful Adjunct Tools for Causality Assessment. <i>American Journal of Gastroenterology</i> , 2021, 116, 2151-2152.	0.2	9
14	Novel predictors for liver transplantation or death in drug-induced acute liver failure. <i>European Journal of Gastroenterology and Hepatology</i> , 2021, Publish Ahead of Print, .	0.8	1
15	P041 Tandem mass tag-based quantitative proteomic profiling identifies novel putative serum biomarkers for the diagnosis of drug-induced liver injury in patients. , 2021, , .		1
16	Albumin Might Attenuate Bacteria-Induced Damage on Kupffer Cells for Patients with Chronic Liver Disease. <i>Cells</i> , 2021, 10, 2298.	1.8	3
17	Risk of recurrent hepatic encephalopathy in patients with liver cirrhosis: a German registry study. <i>European Journal of Gastroenterology and Hepatology</i> , 2021, 33, 1185-1193.	0.8	10
18	To Protect Fatty Livers from Ischemia Reperfusion Injury: Role of Ischemic Postconditioning. <i>Digestive Diseases and Sciences</i> , 2021, 66, 1349-1359.	1.1	0

#	ARTICLE	IF	CITATIONS
19	Biomarkers of idiosyncratic drug-induced liver injury (DILI) - a systematic review. Expert Opinion on Drug Metabolism and Toxicology, 2021, 17, 1327-1343.	1.5	10
20	Drug-Induced Liver Injury (DILI): A Major Challenge. Drug Research, 2021, 71, S7-S7.	0.7	2
21	Age independent survival benefit for patients with hepatocellular carcinoma (HCC) without metastases at diagnosis: a population-based study. Gut, 2020, 69, 168-176.	6.1	67
22	Patients with cirrhosis and SBP: Increase in multidrug-resistant organisms and complications. European Journal of Clinical Investigation, 2020, 50, e13198.	1.7	8
23	Blood metabolomics uncovers inflammation-associated mitochondrial dysfunction as a potential mechanism underlying ACLF. Journal of Hepatology, 2020, 72, 688-701.	1.8	223
24	Recent advances in alcohol-related liver disease (ALD): summary of a Gut round table meeting. Gut, 2020, 69, 764-780.	6.1	112
25	The PREDICT study uncovers three clinical courses of acutely decompensated cirrhosis that have distinct pathophysiology. Journal of Hepatology, 2020, 73, 842-854.	1.8	282
26	IL-18 But Not IL-1 Signaling Is Pivotal for the Initiation of Liver Injury in Murine Non-Alcoholic Fatty Liver Disease. International Journal of Molecular Sciences, 2020, 21, 8602.	1.8	14
27	Acute liver injury in a patient with adult-onset Still's disease—the challenge of differential diagnosis. Oxford Medical Case Reports, 2020, 2020, omaa102.	0.2	1
28	Metabolic implication of tigecycline as an efficacious second-line treatment for sorafenib-resistant hepatocellular carcinoma. FASEB Journal, 2020, 34, 11860-11882.	0.2	13
29	Drug-Induced Liver Injury by Checkpoint Inhibitors: Benefit of a Causality Assessment Tool. Hepatology Communications, 2020, 4, 1552-1554.	2.0	0
30	Pretreatment with zinc protects Kupffer cells following administration of microbial products. Biomedicine and Pharmacotherapy, 2020, 127, 110208.	2.5	4
31	Albumin in decompensated cirrhosis: new concepts and perspectives. Gut, 2020, 69, 1127-1138.	6.1	190
32	Kupffer cell activation by different microbial lysates: Toll-like receptor 2 plays pivotal role on thromboxane A ₂ production in mice and humans. European Journal of Immunology, 2020, 50, 1988-1997.	1.6	2
33	HDL-related biomarkers are robust predictors of survival in patients with chronic liver failure. Journal of Hepatology, 2020, 73, 113-120.	1.8	58
34	Prognostic Significance and Functional Relevance of Olfactomedin 4 in Early-Stage Hepatocellular Carcinoma. Clinical and Translational Gastroenterology, 2020, 11, e00124.	1.3	6
35	Inhibition of Cyclin-Dependent Kinase 5: A Strategy to Improve Sorafenib Response in Hepatocellular Carcinoma Therapy. Hepatology, 2019, 69, 376-393.	3.6	38
36	Drug-Drug Combinations Can Enhance Toxicity as Shown by Monocyte-Derived Hepatocyte-like Cells From Patients With Idiosyncratic Drug-Induced Liver Injury. Toxicological Sciences, 2019, 171, 296-302.	1.4	14

#	ARTICLE	IF	CITATIONS
37	Early ALT response to corticosteroid treatment distinguishes idiosyncratic drug-induced liver injury from autoimmune hepatitis. <i>Liver International</i> , 2019, 39, 1906-1917.	1.9	33
38	Ischemic Postconditioning (IPostC) Protects Fibrotic and Cirrhotic Rat Livers after Warm Ischemia. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2019, 2019, 1-11.	0.8	2
39	Predictors of ribociclib-mediated antitumour effects in native and sorafenib-resistant human hepatocellular carcinoma cells. <i>Cellular Oncology (Dordrecht)</i> , 2019, 42, 705-715.	2.1	18
40	Antifibrotic effects of hypocalcemic vitamin D analogs in murine and human hepatic stellate cells and in the CCl4 mouse model. <i>Laboratory Investigation</i> , 2019, 99, 1906-1917.	1.7	19
41	Effects of Albumin Treatment on Systemic and Portal Hemodynamics and Systemic Inflammation in Patients With Decompensated Cirrhosis. <i>Gastroenterology</i> , 2019, 157, 149-162.	0.6	178
42	Acute Liver Failure During Pirfenidone Treatment Triggered by Co-medication With Esomeprazole. <i>Hepatology</i> , 2019, 70, 1869-1871.	3.6	10
43	Addressing Profiles of Systemic Inflammation Across the Different Clinical Phenotypes of Acutely Decompensated Cirrhosis. <i>Frontiers in Immunology</i> , 2019, 10, 476.	2.2	134
44	Evaluating the best empirical antibiotic therapy in patients with acute-on-chronic liver failure and spontaneous bacterial peritonitis. <i>Digestive and Liver Disease</i> , 2019, 51, 1300-1307.	0.4	13
45	The PI3K inhibitor copanlisib synergizes with sorafenib to induce cell death in hepatocellular carcinoma. <i>Cell Death Discovery</i> , 2019, 5, 86.	2.0	41
46	Epidemiology and Effects of Bacterial Infections in Patients With Cirrhosis Worldwide. <i>Gastroenterology</i> , 2019, 156, 1368-1380.e10.	0.6	296
47	Prevalence and short-term mortality of acute-on-chronic liver failure: A national cohort study from the USA. <i>Journal of Hepatology</i> , 2019, 70, 639-647.	1.8	101
48	Multidrug-resistant bacterial infections in patients with decompensated cirrhosis and with acute-on-chronic liver failure in Europe. <i>Journal of Hepatology</i> , 2019, 70, 398-411.	1.8	225
49	Orchestration of Tryptophan-Kynurenine Pathway, Acute Decompensation, and Acute-on-Chronic Liver Failure in Cirrhosis. <i>Hepatology</i> , 2019, 69, 1686-1701.	3.6	80
50	The Munich-Transarterial Chemoembolisation Score Holds Superior Prognostic Capacities Compared to TACE-Tailored Modifications of 9 Established Staging Systems for Hepatocellular Carcinoma. <i>Digestion</i> , 2019, 100, 15-26.	1.2	5
51	The effects of hepatic steatosis on thromboxane A2 induced portal hypertension. <i>Gastroenterology</i> , 2019, 42, 534-541.	0.2	1
52	Association Between Grade of Acute on Chronic Liver Failure and Response to Terlipressin and Albumin in Patients With Hepatorenal Syndrome. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 1792-1800.e3.	2.4	127
53	Mitochondrial adaptation in steatotic mice. <i>Mitochondrion</i> , 2018, 40, 1-12.	1.6	54
54	Cell death markers in patients with cirrhosis and acute decompensation. <i>Hepatology</i> , 2018, 67, 989-1002.	3.6	76

#	ARTICLE	IF	CITATIONS
55	Development and Validation of a Test to Identify Drugs That Cause Idiosyncratic Drug-Induced Liver Injury. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 1488-1494.e5.	2.4	45
56	Herbal tea and liver injury – Tea extract or comedication can make a difference. <i>Journal of Hepatology</i> , 2018, 69, 547-548.	1.8	7
57	Proteomics Analysis of Monocyte-Derived Hepatocyte-Like Cells Identifies Integrin Beta 3 as a Specific Biomarker for Drug-Induced Liver Injury by Diclofenac. <i>Frontiers in Pharmacology</i> , 2018, 9, 699.	1.6	23
58	Secondary prophylaxis for variceal bleeding: carvedilol vs. propranolol. <i>Hepatology International</i> , 2017, 11, 141-142.	1.9	0
59	Plasma cystatin C is a predictor of renal dysfunction, acute-on-chronic liver failure, and mortality in patients with acutely decompensated liver cirrhosis. <i>Hepatology</i> , 2017, 66, 1232-1241.	3.6	72
60	Tapering of Immunosuppression and Sustained Treatment With Nivolumab in a Liver Transplant Recipient. <i>Gastroenterology</i> , 2017, 152, 1631-1633.	0.6	59
61	Drug-induced liver injury: recent advances in diagnosis and risk assessment. <i>Gut</i> , 2017, 66, 1154-1164.	6.1	370
62	Data on chow, liver tissue and mitochondrial fatty acid compositions as well as mitochondrial proteome changes after feeding mice a western diet for 24 weeks. <i>Data in Brief</i> , 2017, 15, 163-169.	0.5	9
63	Systemic inflammation in decompensated cirrhosis: Characterization and role in acute-on-chronic liver failure. <i>Hepatology</i> , 2016, 64, 1249-1264.	3.6	550
64	Monocyte-derived hepatocyte-like cells for causality assessment of idiosyncratic drug-induced liver injury. <i>Gut</i> , 2016, 65, 1555-1563.	6.1	48
65	Rescue management of early complications after liver transplantation – key for the long-term success. <i>Langenbeck's Archives of Surgery</i> , 2016, 401, 389-396.	0.8	5
66	Reliable Quantification of the Potential for Equations Based on Spot Urine Samples to Estimate Population Salt Intake: Protocol for a Systematic Review and Meta-Analysis. <i>JMIR Research Protocols</i> , 2016, 5, e190.	0.5	4
67	Role of interleukin-1 and its antagonism of hepatic stellate cell proliferation and liver fibrosis in the Abcb4 ^{-/-} mouse model. <i>World Journal of Hepatology</i> , 2016, 8, 401.	0.8	40
68	Clinical Course of acute-on-chronic liver failure syndrome and effects on prognosis. <i>Hepatology</i> , 2015, 62, 243-252.	3.6	493
69	Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites. <i>Gut</i> , 2015, 64, 531-537.	6.1	405
70	The CLIF Consortium Acute Decompensation score (CLIF-C ADs) for prognosis of hospitalised cirrhotic patients without acute-on-chronic liver failure. <i>Journal of Hepatology</i> , 2015, 62, 831-840.	1.8	289
71	Targeting cyclin dependent kinase 5 in hepatocellular carcinoma – A novel therapeutic approach. <i>Journal of Hepatology</i> , 2015, 63, 102-113.	1.8	72
72	Development and validation of a prognostic score to predict mortality in patients with acute-on-chronic liver failure. <i>Journal of Hepatology</i> , 2014, 61, 1038-1047.	1.8	741

#	ARTICLE	IF	CITATIONS
73	Acute-on-Chronic Liver Failure Is a Distinct Syndrome That Develops in Patients With Acute Decompensation of Cirrhosis. <i>Gastroenterology</i> , 2013, 144, 1426-1437.e9.	0.6	2,211
74	Satavaptan for the management of ascites in cirrhosis: efficacy and safety across the spectrum of ascites severity. <i>Gut</i> , 2012, 61, 108-116.	6.1	121
75	Human monocyte-derived cells with individual hepatocyte characteristics: a novel tool for personalized in vitro studies. <i>Laboratory Investigation</i> , 2012, 92, 926-936.	1.7	29
76	TIPS for the treatment of refractory ascites, hepatorenal syndrome and hepatic hydrothorax: a critical update. <i>Gut</i> , 2010, 59, 988-1000.	6.1	208
77	Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. <i>Postgraduate Medical Journal</i> , 2008, 84, 662-670.	0.9	504
78	The patient with refractory ascites. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2007, 21, 551-560.	1.0	16
79	Liver injury and liver protection: mechanisms and novel treatment strategies. <i>Liver International</i> , 2006, 26, 902-903.	1.9	5
80	Progress in treatment of massive ascites and hepatorenal syndrome. <i>World Journal of Gastroenterology</i> , 2006, 12, 516.	1.4	11
81	Benefit of TIPS for patients with refractory or recidivant ascites: Serum bilirubin may make the difference. <i>Hepatology</i> , 2005, 41, 217-217.	3.6	23
82	Rapid development of esophageal squamous cell carcinoma after liver transplantation for alcohol-induced cirrhosis. <i>Transplant International</i> , 2003, 16, 639-641.	0.8	23
83	Therapy of hyponatremia in cirrhosis with a vasopressin receptor antagonist: A randomized double-blind multicenter trial. <i>Gastroenterology</i> , 2003, 124, 933-939.	0.6	280
84	Improved Quality of Life in Patients with Refractory or Recidivant Ascites after Insertion of Transjugular Intrahepatic Portosystemic Shunts. <i>Digestion</i> , 2002, 66, 127-130.	1.2	52
85	In-vivo quantification of hepatic 11 β -hydroxysteroid dehydrogenase type I activity—a preliminary study. <i>Clinical Biochemistry</i> , 2002, 35, 655-657.	0.8	6
86	Short-term treatment with mycophenolic acid increases bile flow in continuously perfused and cold-preserved rat livers and does not affect hepatic ischemia-reperfusion injury. <i>Transplant International</i> , 2002, 15, 265-271.	0.8	2
87	Hepatic arterial buffer response in patients with advanced cirrhosis. <i>Hepatology</i> , 2002, 35, 630-634.	3.6	122
88	Determination of plasma adrenomedullin concentrations with commercial radioimmunoassay kits: A note of caution. <i>Liver Transplantation</i> , 2000, 6, 384-386.	1.3	4
89	A Comparison of Paracentesis and Transjugular Intrahepatic Portosystemic Shunting in Patients with Ascites. <i>New England Journal of Medicine</i> , 2000, 342, 1701-1707.	13.9	531
90	Prevention of Kupffer cell-induced oxidant injury in rat liver by atrial natriuretic peptide. <i>American Journal of Physiology - Renal Physiology</i> , 1999, 276, G1137-G1144.	1.6	53

#	ARTICLE	IF	CITATIONS
91	Hepatic blood flow and splanchnic oxygen consumption in patients with liver failure. Effect of high-volume plasmapheresis. <i>Hepatology</i> , 1999, 29, 347-355.	3.6	68
92	Long-term therapy and retreatment of hepatorenal syndrome type 1 with ornipressin and dopamine. <i>Hepatology</i> , 1999, 30, 870-875.	3.6	177
93	Renal effects of transjugular intrahepatic portosystemic shunt in cirrhosis: Comparison of patients with ascites, with refractory ascites, or without ascites. <i>Hepatology</i> , 1998, 28, 683-688.	3.6	73
94	The guanylate cyclase-coupled natriuretic peptide receptor: A new target for prevention of cold ischemia-reperfusion damage of the rat liver. <i>Hepatology</i> , 1998, 28, 1309-1317.	3.6	64
95	Endothelin-1 and -3 plasma concentrations in patients with cirrhosis: Role of splanchnic and renal passage and liver function. <i>Hepatology</i> , 1995, 21, 735-739.	3.6	101
96	Advantages of the new loop diuretic torasemide over furosemide in patients with cirrhosis and ascites. <i>Journal of Hepatology</i> , 1993, 17, 353-358.	1.8	43
97	Medical treatment of ascites in cirrhosis. <i>Journal of Hepatology</i> , 1993, 17, S4-S9.	1.8	24
98	Pathophysiology of elevated ascites fluid cholesterol in malignant ascites. <i>Journal of Hepatology</i> , 1992, 14, 244-248.	1.8	25
99	Role of the liver in splanchnic extraction of atrial natriuretic factor in the rat. <i>Hepatology</i> , 1992, 16, 790-793.	3.6	11
100	Estimated central blood volume in cirrhosis: Relationship to sympathetic nervous activity, β_2 -adrenergic blockade and atrial natriuretic factor. <i>Hepatology</i> , 1992, 16, 1163-1170.	3.6	76
101	Estimated central blood volume in cirrhosis: Relationship to sympathetic nervous activity, β_2 -adrenergic blockade and atrial natriuretic factor. <i>Hepatology</i> , 1992, 16, 1163-1170.	3.6	3
102	Ornipressin in the treatment of functional renal failure in decompensated liver cirrhosis. <i>Gastroenterology</i> , 1991, 101, 1060-1067.	0.6	157
103	Altered density of glomerular binding sites for atrial natriuretic factor in bile duct-ligated rats with ascites. <i>Hepatology</i> , 1991, 13, 562-566.	3.6	23
104	Ascitic fluid analysis for the differentiation of malignancy-related and nonmalignant ascites. Proposal of a diagnostic sequence. <i>Cancer</i> , 1991, 68, 1808-1814.	2.0	61
105	Ascitic fluid concentrations of fibronectin and cholesterol: comparison of differential diagnostic value with the conventional protein determination. <i>Liver</i> , 1990, 10, 152-157.	0.1	15
106	Atrial natriuretic factor and renin-aldosterone in volume regulation of patients with cirrhosis. <i>Hepatology</i> , 1989, 9, 417-422.	3.6	74
107	Value of ascitic lipids in the differentiation between cirrhotic and malignant ascites. <i>Hepatology</i> , 1986, 6, 239-243.	3.6	69